A Multi-Center, Open-Label Efficacy, Safety, and Pharmacokinetic Study of Adalimumab in Japanese Subjects With Active Ankylosing Spondylitis.
Phase of Trial: Phase III
Latest Information Update: 20 Feb 2017
At a glance
- Drugs Adalimumab (Primary)
- Indications Ankylosing spondylitis
- Focus Therapeutic Use
- Sponsors Abbott Laboratories; Eisai Co Ltd
- 10 Jun 2017 Biomarkers information updated
- 24 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Oct 2010 Planned end date changed from 1 Oct 2011 to 1 Jan 2011 as reported by ClinicalTrials.gov.